At­las ramps up a new biotech play­er fo­cused on neu­rol­o­gy, with a $30M round to fund the work

About 6 months ago, Jef­frey Mil­brandt and Aaron DiAnto­nio out of Wash­ing­ton Uni­ver­si­ty pub­lished a high-pro­file pa­per in Neu­ron high­light­ing the role that SARM1 played in the degra­da­tion of ax­ons — a pathol­o­gy that push­es pa­tients with a va­ri­ety of neu­ro­log­i­cal con­di­tions like MS and ALS down a dan­ger­ous path­way.

What they didn’t say at the time was that Ja­son Rhodes, a part­ner at At­las Ven­ture, was al­ready seed­ing the foun­da­tion­al sci­ence work on SARM1 that would go in­to a new com­pa­ny that is hav­ing its com­ing out par­ty to­day. The Cam­bridge, MA-based biotech up­start is called Dis­arm Ther­a­peu­tics, and it’s leap­ing on­to the biotech stage with a $30 mil­lion round to ad­vance a pipeline of SARM1 in­hibitors for a va­ri­ety of dis­eases.

The sci­en­tif­ic ex­plo­ration goes back to 2012, Rhodes tells me, so by the time he got in­volved in the com­pa­ny-build­ing ef­fort the two in­ves­ti­ga­tors were al­ready well down the road on the dis­cov­ery work, ex­am­in­ing the role of an ac­tive en­zyme in at­tack­ing ax­ons.

“The goal is to re­duce the rate of de­cay, sta­bi­lize it,” Rhodes ex­plains. “You can ac­tu­al­ly re­verse and re­cov­er dam­aged ax­ons.” In a dis­ease like MS, adding one of their drugs to a stan­dard of care treat­ment could re­duce the mag­ni­tude and fre­quen­cy of the flares that dam­age pa­tients brains.

“Most get sec­ondary pro­gres­sive dis­ease,” says Rhodes, “which is de­fined by a loss of ax­on­al vol­ume.”

“One of the main goals was to de-risk the bi­ol­o­gy in a hu­man neu­ronal cell cul­ture, look at dam­age af­ter an acute in­sult,” says Raj De­vraj, the co-founder and CSO at Dis­arm. “That gave us a lot of con­fi­dence,” he says, adding that the group want­ed to nail down IP for a broad port­fo­lio fo­cused on mech­a­nisms of ac­tion.

Dis­arm will be pur­su­ing a fa­mil­iar, se­mi-vir­tu­al mod­el with this com­pa­ny, which Rhodes will helm through the start­up pe­ri­od. That calls for a small but ex­pert team work­ing with out­sourc­ing groups like Evotec, where they en­joy some long­stand­ing re­la­tion­ships. The Cam­bridge crowd will rec­og­nize De­vraj, the CSO at Michael Gilman’s for­mer com­pa­ny Pad­lock (be­fore it was bought out) and one of the go-to sci­en­tists at At­las.

Of note, Bio­gen’s Al San­drock is join­ing the board as an in­de­pen­dent mem­ber. Bio­gen’s MS drugs have changed the stan­dard of care in MS and he brings some deep ex­per­tise in the field.

At­las Ven­ture led the round, of course, with co-in­vestors Light­stone Ven­tures and Ab­b­Vie Ven­tures step­ping in along­side.


Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,800+ biopharma pros reading Endpoints daily — and it's free.

We­bi­nar: Re­al World End­points — the brave new world com­ing in build­ing fran­chise ther­a­pies

Several biopharma companies have been working on expanding drug labels through the use of real world endpoints, combing through the data to find evidence of a drug’s efficacy for particular indications. But we’ve just begun. Real World Evidence is becoming an important part of every clinical development plan, in the soup-through-nuts approach used in building franchises.

I’ve recruited a panel of 3 top experts in the field — the first in a series of premium webinars — to look at the practical realities governing what can be done today, and where this is headed over the next few years, at the prodding of the FDA.

ZHEN SU — Merck Serono’s Senior Vice President and Global Head of Oncology

ELLIOTT LEVY — Amgen’s Senior Vice President of Global Development

CHRIS BOSHOFF — Pfizer Oncology’s Chief Development Officer

A premium subscription to Endpoints News is required to attend this webinar. Please upgrade to either an Insider or Enterprise plan for access. Already have Endpoints Premium? Please sign-in below. You can contact our Subscriptions team at with any issues.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Video: Putting the AI in R&D — with Badhri Srini­vasan, Tony Wood, Rosana Kapeller, Hugo Ceule­mans, Saurabh Sa­ha and Shoibal Dat­ta

During BIO this year, I had a chance to moderate a panel among some of the top tech experts in biopharma on their real-world use of artificial intelligence in R&D. There’s been a lot said about the potential of AI, but I wanted to explore more about what some of the larger players are actually doing with this technology today, and how they see it advancing in the future. It was a fascinating exchange, which you can see here. The transcript has been edited for brevity and clarity. — John Carroll

UP­DAT­ED: As­traZeneca’s Imfinzi/treme com­bo strikes out — again — in lung can­cer. Is it time for last rites?

AstraZeneca bet big on the future of their PD-L1 Imfinzi combined with the experimental CTLA-4 drug tremelimumab. But once again it’s gone down to defeat in a major Phase III study — while adding damage to the theory involving targeting cancer with a high tumor mutational burden.

Early Wednesday the pharma giant announced that their NEPTUNE study had failed, with the combination unable to beat standard chemo at overall survival in high TMB cases of advanced non-small cell lung cancer. We won’t get hard data until later in the year, but the drumbeat of failures will call into question what — if any — future this combination can have left.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,800+ biopharma pros reading Endpoints daily — and it's free.

Ted Ashburn. Oncorus

Cowen, Per­cep­tive lead $79.5M Se­ries B for 's­tand­out' biotech shep­herd­ing on­colyt­ic virus to clin­ic

As several Big Pharma players secure biotech partners in the oncolytic virus space for new immuno-oncology combos, Cowen and Perceptive Advisors have come out with their own bet on a startup that promises to shine.

The marquee investors are joining MPM, Deerfield, Celgene, Astellas, Arkin and UBS in backing the drug developer, Oncorus, which will now deploy the $79.5 million in Series B cash toward clinical development of its lead program. Other new investors include Surveyor Capital, Sphera Funds, IMM Investment, QUAD Investment Management, UTC Investment, SV Investment Corp and Shinhan Investment-Private Equity, the last five of which are Korean-based funds.

Fu­til­i­ty analy­sis au­gurs de­feat in piv­otal tri­al test­ing of Nu­Cana's lead drug in metasta­t­ic pan­cre­at­ic can­cer

Nearly two years after making its public debut, UK-based NuCana’s mission to make chemotherapies more potent and safer was dealt a blow, after a pivotal study testing its lead experimental drug halted enrollment in a hard-to-treat advanced form of cancer, following a futility analysis.

The drug, Acelarin, is being evaluated for use in metastatic pancreatic cancer patients who were not considered suitable for combination chemotherapy. In the late-stage ACELARATE study — which compared the experimental drug against the chemotherapy gemcitabine — 200 patients had been enrolled by the sponsor, Clatterbridge Cancer Centre, before an analysis from an independent safety and data monitoring panel suggested the study’s main goal would not be met.

UP­DAT­ED: Pay­back? An­a­lysts say Sarep­ta was blind­sided by an FDA re­jec­tion dri­ven by reg­u­la­to­ry re­venge

In one of the least anticipated moves of the year, the FDA has rejected Sarepta’s application for an accelerated approval of its Duchenne MD drug golodirsen after fretting over safety issues.

In a statement that arrived after the bell on Monday, Sarepta explained the CRL, saying:

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,800+ biopharma pros reading Endpoints daily — and it's free.

Levi Garraway. Broad Institute via Youtube

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

We found out Monday morning where Levi Garraway was headed after he left Eli Lilly as head of oncology R&D a few days ago. Roche named Garraway as their new chief medical officer, replacing Sandra Horning, who they say is retiring from the company.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,800+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

As Bloomberg notes, most of the Wall Street analysts that cover Sarepta $SRPT are an upbeat bunch, ready to cheer on the team when it comes to their Duchenne MD drugs, or offer explanations when an odd setback occurs — as happened recently with a safety signal that was ‘erroneously’ reported last week.

Ritu Baral Cowen
Endpoints News

Basic subscription required

Unlock this story instantly and join 57,800+ biopharma pros reading Endpoints daily — and it's free.